Enable AccessibilityEnable Accessibility

Arthritis Foundation and Takeda Launch Let’s Speak Gout to Encourage Better Disease Management for Patients with Gouty Arthritis

May 17, 2016

Research Yields New Insights and Tools for Health Care Professionals and Patients

DEERFIELD, Ill. and ATLANTA, GA., May 17, 2016 - Today, the Arthritis Foundation and Takeda Pharmaceuticals U.S.A., Inc. (Takeda) launched Let’s Speak Gout, a program based on new joint research, that offers tools for health care professionals (HCPs) and patients to make more effective gouty arthritis (“gout”) management a priority.

Let’s Speak Gout includes insights from both patients and HCPs from new research that separately studied patient discussions about gout and physicians’ reactions to them, as well as physician discussions about gout and patients’ reactions to them. Program materials also reflect insights from separate Arthritis Foundation and Takeda research, as well as from other published studies conducted over the last few years. Based on all this research, the Arthritis Foundation identified important gaps and insights into how HCPs and patients think, act and talk about gout. These insights were used to develop new tools to help enhance the effectiveness of conversations between HCPs and patients with gout.

“Gout can be managed effectively, reducing or eliminating attacks. But, too often, patients are accepting painful gout attacks as a way of life instead of working to better manage the disease with their health care professional,” shares Ann M. Palmer, president and CEO of the Arthritis Foundation. “We chart the course for the arthritis community, helping people develop personalized plans for saying Yes — day after day. The tools developed for Let’s Speak Gout are part of a support system for people with gouty arthritis to navigate conversations with doctors, manage the disease and advocate for themselves.”

Let’s Speak Gout resources for HCPs and patients in the United States are available on the Arthritis Foundation website, www.arthritis.org/lets-speak-gout; the site includes downloadable discussion tools for HCPs and for gout patients, details on the research findings and research methodology. Let’s Speak Gout tool content includes highlights of research findings and a guide to having more effective interactions between HCPs and patients living with gout.

Core Let’s Speak Gout Research Findings
Core Let’s Speak Gout findings to create more effective HCP/patient discussions about gout include:

  • HCPs and patients do not currently share the same definitions for effective gout treatment. They need to establish common goals for number of flares and for uric acid level, then regularly screen and track progress towards those goals
  • Both patients and HCPs overemphasize the dietary component of gout and often overlook the larger genetic component, leaving patients feeling guilty and potentially less honest in discussions with their doctors
  • Both patients and HCPs focus on treating the short-term pain of gout attacks, and do not always address the long-term consequences and potential damage of untreated gout.
  • There are specific ways to shift the tone and content of HCP/patient discussions about gout that may yield more effective interactions and better patient outcomes.

“Takeda is committed to providing patient-focused education and support to improve the treatment and management of gout which is why we are excited to partner with the Arthritis Foundation on Let’s Speak Gout,” said Thomas Gibbs, Senior Vice President, General Medicine Business Unit, Takeda. “Recognizing how health care professionals and patients think and talk about gout is important to disease management. We believe the tools developed in partnership with the Arthritis Foundation will help support health care professionals and provide gout patients valuable education to help them better manage their disease.”

Let’s Speak Gout Research Approach
To develop the Let’s Speak Gout program, the Arthritis Foundation and Takeda began by analyzing existing research conducted separately by the companies, as well as other published studies on HCP and patient perceptions of gout and on doctor-patient communications over the last few years. Then the Arthritis Foundation and Takeda sponsored new research to better identify effective language and approaches for doctor-patient gout communications. This research used an innovative bridge group approach. Patients with gout participated in facilitated focus groups about their condition, while physicians observed behind one-way mirrors. Both the patients and the observing physicians were separately asked by researchers for their perceptions and reactions to different language used. Different physician and gout patient groups also were conducted in the reverse: Physicians participated in facilitated focus groups about gout and its management, while gout patient groups observed behind one-way mirrors. These physician and gout patient cohorts were then also separately asked by researchers for their perceptions and reactions to different language used. Insights gained from all this new research were synthesized with the prior research; all was used to develop the Let’s Speak Gout tools. These resources aim to support and motivate HCPs and gout patients to more effectively communicate and better manage the disease.

About Gouty Arthritis
Gout is caused by a buildup of uric acid in the body. Uric acid forms crystals in the joints, which can lead to the inflammation and pain of a gout attack. As the uric acid level rises, so does the chance for gout and gout attacks. Over time, these attacks, or flares, can involve more joints, last longer, and happen more often.

The Arthritis Foundation is strengthening its commitment to the estimated 8.3 million Americans with gout, which may be increasing. Half of gout patients have three or more attacks per year; a typical gout attack can last at least 4 days.

Possible barriers to better gout care may include a focus on painful attacks more than the underlying cause (high serum uric acid), greater urgency put on other disease such as diabetes and cardiovascular disease, and a sense of patient blame due to social stigmas.

About the Arthritis Foundation
The Arthritis Foundation is the Champion of Yes. Leading the fight for the arthritis community, the Foundation helps conquer everyday battles through life-changing information and resources, access to optimal care, advancements in science and community connections. The Arthritis Foundation’s goal is to chart a winning course, guiding families in developing personalized plans for living a full life – and making each day another stride towards a cure. The Foundation also publishes Arthritis Today, the award-winning magazine that reaches four million readers per issue.

About Takeda Pharmaceutical Company 
Takeda Pharmaceutical Company Limited is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on oncology, gastroenterology and central nervous system therapeutic areas. It also has specific development programs in specialty cardiovascular diseases as well as late-stage candidates for vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as its presence in emerging markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.

Takeda Pharmaceuticals U.S.A., Inc. is located in Deerfield, Ill., and is the U.S. marketing and sales organization of Takeda Pharmaceutical Company Limited.

Additional information about Takeda is available through its corporate website, www.takeda.com, and additional information about Takeda Pharmaceuticals U.S.A., Inc. is available through its website, www.takeda.us.



Sandra Mackey
Arthritis Foundation
[email protected]

Linda Calandra
Takeda Pharmaceuticals U.S.A., Inc.
[email protected]

Amy Losak
[email protected]